Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2012

View Archived Issues

Lundbeck reports on second quarter of 2012

Additional causes of startle disease identified / News in Context

Combination regimen shows efficacy in patients with tuberculosis

Astellas Pharma announces highlights for second quarter of 2012

Mitsubishi Tanabe Pharma reviews second quarter 2012

Multiple new global ALS research grants issued

Amylin satisfies financial obligations to Lilly for exenatide

Marqibo receives accelerated approval

Sosei transfers SD-118 rights

Phase III AVAglio trial meets coprimary endpoint

Pirfenidone approved in South Korea

Novel pim kinase inhibitors synthesized in Spain

Research in Malaysia yields new curcumin derivatives

Novel GPR119 agonists disclosed by Boehringer Ingelheim Pharma

Convergence Pharmaceuticals reports novel candidate analgesics

Scientists in Italy and U.S. jointly develop new 3-HAO inhibitors

German team designs new candidate drugs for cardiovascular diseases

Recombinant hypoallergenic combination vaccines developed for house dust mite allergy

Intercept Pharmaceuticals secures funds for development of its lead product

Data presented on temsirolimus combination regimen in kidney cancer

FDA places clinical hold on anthrax vaccine program

Elan announces planned spin-off

FDA approves first drug for diabetic macular edema

Pluristem Therapeutics reports on PLX-PAD trial

Phase III study of OCV-C01 advances

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...